Last reviewed · How we verify
Aspirin or thienopyridine
Aspirin and thienopyridines inhibit platelet aggregation through different pathways to prevent blood clots and reduce cardiovascular events.
Aspirin and thienopyridines inhibit platelet aggregation through different pathways to prevent blood clots and reduce cardiovascular events. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Ischemic stroke prevention.
At a glance
| Generic name | Aspirin or thienopyridine |
|---|---|
| Sponsor | Associations for Establishment of Evidence in Interventions |
| Drug class | Antiplatelet agents |
| Target | COX-1 (aspirin); P2Y12 receptor (thienopyridines) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), blocking thromboxane A2 production and platelet activation. Thienopyridines (clopidogrel, prasugrel, ticagrelor) are P2Y12 adenosine diphosphate receptor antagonists that prevent platelet aggregation. Together or individually, they reduce thrombotic complications in cardiovascular disease.
Approved indications
- Acute coronary syndrome
- Secondary prevention after myocardial infarction
- Ischemic stroke prevention
- Peripheral arterial disease
- Coronary stent thrombosis prevention
Common side effects
- Bleeding
- Gastrointestinal bleeding (aspirin)
- Dyspepsia
- Thrombotic thrombocytopenic purpura (thienopyridines)
- Neutropenia (thienopyridines)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) (PHASE3)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: